Published in AIDS Weekly and Law, January 19th, 2006
The data provide fresh evidence further supporting a new therapeutic strategy for treatment-experienced HIV patients, which was recently recommended in updated antiretroviral treatment guidelines from the U.S. Department of Health and Human Services (DHHS). Fuzeon, codeveloped by Roche and Trimeris (TRMS), is the first and only...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly and Law
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.